Dr. Ruchi Mathur, MD

Dr. Mathur practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Mathur's NPI, 1184650749, was assigned on June 24, 2006. Dr. Mathur graduated from University of Manitoba in 1992. Dr. Mathur holds California license A60575.

Dr. Mathur's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Mathur's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Mathur to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mathur practices, 2 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Mathur's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Mathur is licensed in California.

Dmand AI lists chronic diabetes, diabetic emergency, high cholesterol, obesity, osteoporosis, overactive thyroid and underactive thyroid among the conditions Dr. Mathur treats.

CMS data shows 146 Medicare services from Dr. Mathur across 3 procedure codes in 2024, for 67 Medicare patients. Medicare paid $6,608 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 67 Medicare patients who saw Dr. Mathur in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mathur's median patient age at 68, with 60% women.

In 2024, Dr. Mathur wrote 459 Medicare Part D claims for 49 patients. 41% of them were for generic drugs. CMS names the drug for 299 of them, across 14 drugs with 11 or more claims each, at $121,250 in total drug cost. In 2023, CMS named 291 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mathur for performance year 2024, reported as part of a group. Dr. Mathur accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mathur as offering telehealth.

Dmand AI links 17 papers to Dr. Mathur, published from 2014 to 2025. Dr. Mathur's most frequent co-authors are Mark Pimentel, MD, Ali Rezaie and Ricardo Azziz, MD.

Dmand AI links Dr. Mathur to 4 clinical trials. Conditions studied include Diabetes Mellitus, Type 2, Obesity and Diabetes Mellitus. Cedars-Sinai Medical Center sponsors the most, 2.

CMS Open Payments shows 15 general payments to Dr. Mathur from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. Novo Nordisk Inc paid the most, $226. It also lists 1 research payment totaling $100,000 in 2017.

Dmand AI lists 11 awards for Dr. Mathur, most recently America’s Top Physicians in 2021.

Dr. Mathur graduated from University of Manitoba in 1992. Dr. Mathur is a member of AACE and ENDO.

Dr. Mathur is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.